AimsIt is not clear whether there are differences in glycemic control between the Equil patch and the MMT‐712 insulin pump. Our objective was to compare two types of insulin pumps in the treatment of type 2 diabetes mellitus (T2DM), using continuous glucose monitoring (CGM) metrics and profiles.MethodsThis was a randomized case‐crossover clinical trial. Participants were hospitalized and randomly allocated to two groups and underwent two types of insulin pump treatments (group A: Equil patch—Medtronic MMT‐712 insulin pump; group B: Medtronic MMT‐712—Equil patch insulin pump) separated by a 1‐day washout period. Glycemic control was achieved after 7–8 days of insulin pump therapy. Each patient received CGM for 5 consecutive days (from day 1 to day 5). On day 3 of CGM performance, the Equil patch insulin pump treatment was switched to Medtronic MMT‐712 insulin pump treatment at the same basal and bolus insulin doses or vice versa. CGM metrics and profiles including glycemic variability (GV), time in range (TIR, 3.9–10.0 mmol/L), time below range (TBR, <3.9 mmol/L), time above range (TAR, >10.0 mmol/L), and postprandial glucose excursions, as well as incidence of hypoglycemia.ResultsForty‐six T2DM patients completed the study. There was no significant difference in parameters of daily GV and postprandial glucose excursions between the Equil patch insulin pump treatment and the Medtronic insulin pump treatment. Similarly, there was no between‐treatment difference in TIR, TBR, and TAR, as well as the incidence of hypoglycemia.imageConclusionThe Equil patch insulin pump was similar to the traditional MMT‐712 insulin pump in terms of glycemic control. Equil patch insulin pump is a reliable tool for glycemic management of diabetes mellitus.

中文翻译：

---

使用连续血糖监测指标和概况比较 Equil 贴片与传统导管胰岛素泵在 2 型糖尿病中的作用

目的尚不清楚 Equil 贴片和 MMT-712 胰岛素泵在血糖控制方面是否存在差异。我们的目标是使用连续血糖监测 (CGM) 指标和概况来比较两种类型的胰岛素泵治疗 2 型糖尿病 (T2DM) 的效果。方法这是一项随机病例交叉临床试验。参与者住院并随机分为两组，并接受两种类型的胰岛素泵治疗（A 组：Equil 贴片 - 美敦力 MMT-712 胰岛素泵；B 组：美敦力 MMT-712 - Equil 贴片胰岛素泵），间隔 1 天冲洗期。胰岛素泵治疗 7-8 天后血糖得到控制。每个患者连续 5 天（从第 1 天到第 5 天）接受 CGM。在 CGM 表现的第 3 天，将 Equil 贴片胰岛素泵治疗改为美敦力 MMT-712 胰岛素泵治疗，基础剂量和推注胰岛素剂量相同，反之亦然。 CGM 指标和概况，包括血糖变异性 (GV)、范围内时间 (TIR，3.9–10.0 mmol/L)、低于范围的时间 (TBR，<3.9 mmol/L)、高于范围的时间 (TAR，>10.0 mmol/L) 、餐后血糖波动以及低血糖发生率。 结果 46 名 T2DM 患者完成了研究。 Equil 贴片胰岛素泵治疗和美敦力胰岛素泵治疗之间的每日 GV 和餐后血糖波动参数没有显着差异。同样，TIR、TBR 和 TAR 以及低血糖发生率也没有治疗间差异。图像结论 Equil 贴片胰岛素泵在血糖控制方面与传统 MMT-712 胰岛素泵相似。 Equil 贴片胰岛素泵是糖尿病血糖管理的可靠工具。